International Journal of Academic Multidisciplinary Research (IJAMR)   Year: 2021 | Volume: 5 | Issue: 11 | Page No.: 32-37 Impact of Direct-Acting Antiviral Therapy on Hepatitis C Patients of Pakistan Muhammad Jamil Awan, Maria Anwar Khan, Humna Babar, Syeda Amna Batool & Samavia Siddique Abstract: HCV (Hepatitis C virus) is the 7th most deadly disease globally with over 150 million people infected worldwide. Pakistan has the second-highest rank of hepatitis C in the world with approximately 10 million HCV infected individuals. Only 1% of HCV infected people are taking treatment in Pakistan. The aim of the study is to determine the efficiency of ribavirin and sofosbuvir on HCV patients in Pakistan. Study was conducted at Department of Molecular Biology, Gulab Devi Educational Complex Lahore from August 2018-April 2019 which included a total of 204 patients with chronic hepatitis C. According to guidelines of the Asia Pacific Association for the Study of Liver (APASL), FDA approved drugs sofosbuvir plus ribavirin were given to these patients for 24 weeks to calculate the early virological response (EVR) and end treatment response (ETR). Peripheral blood samples were collected and routine investigation was performed including serum urea & creatinine, hemoglobin, total leukocyte count, and liver function tests (Serum Bilirubin, ALT, AST & ALP). The study involved 90 male (44.12%) and 114 female (55.88%) HCV patients for DAAs (Direct-Acting Antiviral) therapy. Out of 204 individuals 199 (97.54%) showed ETR (end treatment response) and recovered, while 5 (2.48%) showed NTR (no treatment response) and did not recover. Sofosbuvir plus ribavirin treatment is observed to be an economical and efficient treatment with extra-ordinary end treatment response (97.54%) in HCV patients. This association has high viral eradication rate and improves the liver function as well. In conclusion these drugs are highly effective for HCV recovering patients and could be the best possible treatment for HCV.